Answers are grounded in this paper and cite their sources.
The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.
No takes yet. Share an insight, caveat, or question.
A 2017 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: